首页> 美国卫生研究院文献>Drugs in RD >Changes in Levels of Biomarkers Associated with Adipocyte Function and Insulin and Glucagon Kinetics During Treatment with Dapagliflozin Among Obese Type 2 Diabetes Mellitus Patients

【2h】

Changes in Levels of Biomarkers Associated with Adipocyte Function and Insulin and Glucagon Kinetics During Treatment with Dapagliflozin Among Obese Type 2 Diabetes Mellitus Patients

机译：肥胖2型糖尿病患者用达格列净治疗期间与脂肪细胞功能以及胰岛素和胰高血糖素动力学相关的生物标志物水平的变化

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

ObjectivesThis study aimed to investigate changes in levels of biomarkers associated with adipocyte function and insulin and glucagon kinetics after a meal tolerance test (MTT) during treatment with dapagliflozin among obese type 2 diabetes mellitus (T2DM) patients.

机译：目的本研究旨在研究肥胖2型糖尿病（T2DM）患者在接受达格列净治疗期间的进餐耐受性试验（MTT）后与脂肪细胞功能以及胰岛素和胰高血糖素动力学相关的生物标志物水平的变化。

著录项

期刊名称 Drugs in RD
作者
Aki Okamoto; Hirohide Yokokawa; Hironobu Sanada; Toshio Naito;
展开▼
作者单位

展开▼
年(卷),期 2016(16),3
年度 2016
页码 255–261
总页数 7
原文格式 PDF
正文语种
中图分类药学;
关键词

相似文献

外文文献
中文文献
专利

1. Changes in Levels of Biomarkers Associated with Adipocyte Function and Insulin and Glucagon Kinetics During Treatment with Dapagliflozin Among Obese Type 2 Diabetes Mellitus Patients [J] . Aki Okamoto, Hirohide Yokokawa, Hironobu Sanada, Drugs in R&D . 2016,第3期

机译：肥胖2型糖尿病患者用达格列净治疗期间与脂肪细胞功能，胰岛素和胰高血糖素动力学相关的生物标志物水平的变化
2. Association of different biomarkers of renal function with D-dimer levels in patients with type 1 diabetes mellitus (renal biomarkers and D-dimer in diabetes) [J] . Caroline Pereira?Domingueti, Rodrigo Bastos?Fóscolo, Luci Maria S?Dusse, Archives of Endocrinology and Metabolism . 2018,第1期

机译：1型糖尿病患者肾功能的不同生物标志物与D-二聚体水平的关联（糖尿病中的肾脏生物标志物和D-二聚体）
3. Dapagliflozin as an adjunct therapy to insulin in the treatment of patients with type 1 diabetes mellitus [J] . Hector E. Tamez, Alejandra L. Tamez, Lucas A. Garza, Journal of Diabetes and Metabolic Disorders . 2015,第1期

机译：达格列净作为胰岛素的辅助疗法，用于治疗1型糖尿病患者
4. ACE gene I/D polymorphism and obesity in patients with type 2 diabetes mellitus [C] . Sounira Mehri, Mohamed Hammami International Conference on Engineering MIS . 2017

机译：2型糖尿病患者ACE基因I / D多态性与肥胖
5. Modeling of the insulin pathway in insulin therapy to improve normoglycemic control of patients wtih type 1 diabetes mellitus [D] . Chan, Alice 2011

机译：胰岛素治疗中胰岛素途径的建模以改善1型糖尿病患者的正常血糖控制
6. Response: Effects of 6 Months of Dapagliflozin Treatment on Metabolic Profile and Endothelial Cell Dysfunction for Obese Type 2 Diabetes Mellitus Patients without Atherosclerotic Cardiovascular Disease (J Obes Metab Syndr 2020;29:215-21) [O] . Ju-Young Hong, Keun-Young Park, Jong-Dai Kim, 2021

机译：响应：6个月Dapagliflozin治疗对肥胖2型糖尿病患者的代谢型材和内皮细胞功能障碍的影响没有动脉粥样硬化心血管疾病（J Obes Metab Syndr 2020; 29：215-21）
7. Changes in Levels of Biomarkers Associated with Adipocyte Function and Insulin and Glucagon Kinetics During Treatment with Dapagliflozin Among Obese Type 2 Diabetes Mellitus Patients [O] . 2016

机译：肥胖2型糖尿病患者用达格列净治疗期间与脂肪细胞功能以及胰岛素和胰高血糖素动力学相关的生物标志物水平的变化

Changes in Levels of Biomarkers Associated with Adipocyte Function and Insulin and Glucagon Kinetics During Treatment with Dapagliflozin Among Obese Type 2 Diabetes Mellitus Patients

摘要

著录项

相似文献

相关主题

期刊订阅